Alzheimers

While prasinezumab missed its primary endpoint, time-to-event analyses suggest potential in delaying early Parkinson’s disease…

The revival of CNS drug development is being fueled by advancements in neuroimmunology and neurodegeneration, moving beyond…

NICE's rejection of Kisunla raises cost-effectiveness concerns but future approval remains possible pending further evidence

EU regulator cites brain swelling risks, impacting Eisai and Biogen, and sparking concerns over global sales and market perception…

Study confirms ALZmetrix whole blood test can detect people at high risk of developing full Alzheimer’s Disease

The unit will provide support to individuals with neurological conditions such as Alzheimer's, Dementia, and Parkinson's, through…

Brexpiprazole was previously approved in the US to treat adults with major depressive disorder and schizophrenia

The new non-drug method holds promise for preventative therapies

Under the deal, Pfizer will get $75 million upfront and will be eligible for $635 million in potential milestone payments

The drug is indicated for the treatment of dementia of the Alzheimer's type